A5085835787- Thyroid Cancer Diagnosis and Treatment
- BRCA gene mutations in cancer
- Nutrition, Genetics, and Disease
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Cancer-related Molecular Pathways
- Cell Adhesion Molecules Research
- Science, Research, and Medicine
- Cancer-related gene regulation
- Cancer Mechanisms and Therapy
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Cellular Mechanics and Interactions
- CRISPR and Genetic Engineering
- Melanoma and MAPK Pathways
- Salivary Gland Tumors Diagnosis and Treatment
- Wnt/β-catenin signaling in development and cancer
- Myasthenia Gravis and Thymoma
- Renal cell carcinoma treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pituitary Gland Disorders and Treatments
- Colorectal Cancer Surgical Treatments
- Colorectal Cancer Screening and Detection
- HER2/EGFR in Cancer Research
- Cell death mechanisms and regulation
Foundation Medicine (United States)
2017-2024
Editas Medicine (United States)
2017-2023
University of Colorado Anschutz Medical Campus
2018
Massachusetts General Hospital
2013-2016
Harvard University
2013-2016
Boston University
2009-2012
Boston Medical Center
2007-2012
Abstract Purpose: To define the genetic landscape of advanced differentiated and anaplastic thyroid cancer (ATC) identify alterations potential diagnostic, prognostic, therapeutic significance. Experimental Design: The profiles 583 196 ATCs generated with targeted next-generation sequencing cancer-associated gene panels MSK-IMPACT FoundationOne were analyzed. Results: ATC had more per tumor, pediatric papillary fewer tumor when compared other types. DNA mismatch repair deficit activity...
The interaction of programmed cell death-1 and its ligand is widely studied in cancer. Monoclonal antibodies blocking these molecules have had great success but little known about them thyroid We investigated the role PD-L1 cancer with respect to BRAF mutation MAP kinase pathway activity effect anti antibody therapy on tumor regression intra-tumoral immune response alone or combination inhibitor (BRAFi). BRAFV600E cells showed significantly higher baseline expression at mRNA protein levels...
BackgroundEstrogen receptor-positive (ER-positive) metastatic breast cancer is often intractable due to endocrine therapy resistance. Although ESR1 promoter switching events have been associated with endocrine-therapy resistance, recurrent fusion proteins yet be identified in advanced cancer.Patients and methodsTo identify genomic structural rearrangements (REs) including gene fusions acquired we undertook a multimodal sequencing effort three patient cohorts: (i) mate-pair and/or RNAseq 6...
Abstract Purpose: Genomic rearrangements can generate potent oncogenic drivers or disrupt tumor suppressor genes. This study examines the landscape of fusions and detected by liquid biopsy (LBx) circulating DNA (ctDNA) across different cancer types. Experimental Design: LBx from 53,842 patients with 66 solid types were profiled using FoundationOneLiquid CDx, a hybrid-capture sequencing platform that queries 324 cancer-related Tissue biopsies (TBx) FoundationOneCDx used as comparator....
Thyroid carcinoma, which is rare in pediatric patients (age 0-18 years) but more common adolescent and young adult (AYA) 15-39 years), carries the potential for morbidity mortality.Hybrid-capture-based comprehensive genomic profiling (CGP) was performed prospectively on 512 consecutively submitted thyroid carcinomas, including 58 from AYA (PAYA) patients, to identify alterations (GAs), base substitutions, insertions/deletions, copy number alterations, rearrangements. This PAYA data series...
Current treatment for recurrent and aggressive/anaplastic thyroid cancers is ineffective. Novel targeted therapies aimed at the inhibition of mutated oncoprotein BRAFV600E have shown promise in vivo vitro but do not result cellular apoptosis. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis a tumor-selective manner by activating extrinsic apoptotic pathway. Here, we show that TRAIL-R2 agonist antibody, lexatumumab, effectively some cancer cell lines (HTh-7, TPC-1 BCPAP), while...
// Pierre Vanden Borre 1 , Viswanath Gunda David G. McFadden 2 Peter M. Sadow Shohreh Varmeh Maria Bernasconi and Sareh Parangi Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Thyroid Unit, Medicine, Correspondence: Parangi, email: Keywords : Thyroid, BRAF, SRC Received April 3, 2014 Accepted June 24, Published 26, Abstract Anaplastic (ATC) refractory papillary thyroid cancer (PTC) lack effective treatments. Inhibition either oncogenic BRAF or has...
Over-expression of AND-34/BCAR3/NSP2 (BCAR3) or its binding-partner p130Cas/BCAR1 generates anti-estrogen resistance in human breast cancer lines. Here, we have compared BCAR3 to two related homologs, NSP1 and NSP3/CHAT/SHEP, with regards expression, resistance, signaling. is expressed at higher levels ERalpha-negative, mesenchymal, than ERalpha-positive, epithelial, cell Characterization "intermediate" epithelial-like lines variable ER-alpha expression reveals that correlates both...
Background: While the development of new treatments for aggressive thyroid cancer has advanced in last 10 years, progress trailed headways made with other malignancies. A lack reliable authenticated human cell lines and reproducible animal models is one major roadblock to preclinical testing novel therapeutics. Existing xenograft orthotopic mouse rely on implantation highly passaged carcinoma immunodeficient mice. Genetically engineered papillary undifferentiated (anaplastic) (PTC ATC) are...
Comprehensive genomic profiling (CGP) is a next-generation sequencing-based methodology that detects 4 classes of alterations, as well gene signature biomarkers such microsatellite instability and tumor mutational burden. In the context precision oncology, CGP can help to direct treatment genomically matched therapies.
The focal adhesion adapter protein p130(cas) regulates and growth factor-related signaling, in part through Src-mediated tyrosine phosphorylation of p130(cas). AND-34/BCAR3, one three NSP family members, binds the carboxyl terminus, adjacent to a bipartite Src-binding domain (SBD) induces anti-estrogen resistance breast cancer cell lines as well Only subset signaling properties BCAR3, specifically augmented motility, are dependent upon formation BCAR3-p130(cas) complex. Using GST pull-down...
<p>Supplementary Figures</p>
<div>AbstractPurpose:<p>Genomic rearrangements can generate potent oncogenic drivers or disrupt tumor suppressor genes. This study examines the landscape of fusions and detected by liquid biopsy (LBx) circulating DNA (ctDNA) across different cancer types.</p>Experimental Design:<p>LBx from 53,842 patients with 66 solid types were profiled using FoundationOneLiquid CDx, a hybrid-capture sequencing platform that queries 324 cancer-related Tissue biopsies (TBx)...
<p>Supplementary Tables</p>
<p>Supplementary Figures</p>
<p>Supplementary Tables</p>
<div>AbstractPurpose:<p>Genomic rearrangements can generate potent oncogenic drivers or disrupt tumor suppressor genes. This study examines the landscape of fusions and detected by liquid biopsy (LBx) circulating DNA (ctDNA) across different cancer types.</p>Experimental Design:<p>LBx from 53,842 patients with 66 solid types were profiled using FoundationOneLiquid CDx, a hybrid-capture sequencing platform that queries 324 cancer-related Tissue biopsies (TBx)...
Abstract Background: The MAPK and Src signaling pathways have emerged as critical drivers mediators of papillary anaplastic (PTC ATC) thyroid cancer progression the individual inhibition either pathway has marked anti-tumor effects in mouse models. Unfortunately, neither drug induces apoptosis resistance may develop when is used. We postulated that would further sensitize BRAFV600E-positive cells to PLX4720 treatment. Methods: Proliferation were analyzed four novel murine PTC ATC cell lines...